Press Releases
About Syncromune
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to developing SYNC-T, a completely in situ immunotherapy platform optimized for solid tumor cancers that combines partial oncolysis and a multi-target biologic drug infusion. The platform is designed to achieve personalized T cell activation, empowering the immune system to recognize and attack cancer throughout the body. A Phase 2a trial of the first candidate, SV-102, is currently underway.
Syncromune in the News
Greg Slabodkin, Heather McKenzie and Tyler Patchen | BioSpace | April 9, 2024
AACR 2024: What Cancer Researchers Are Talking About
Anette Breindl | BioWorld | April 8, 2024
AACR 24: Freezing, of all things, is one way to heat cold tumors
George Prendergast, Ph.D. | VJOncology | April 8, 2024
AACR 2024 | Preclinical modeling of cryo-immune vaccination in solid tumors
AACR 2024 | SYNC-T combination immunotherapy in mCRPC
AACR 2024 | The advantages of cryo-immune vaccinations in treating metastatic cancers
Presentations
Upcoming Events
The following are meetings and conferences that the Syncromune team plans to attend. If you would like to meet with one of our team members, please email us at info@syncromune.com
April 25-30, 2025
McCormick Place
Chicago, IL
AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
Conference information: AACR 2025
May 30-June 3, 2025
McCormick Place
Chicago, IL
2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Conference information: ASCO 2025
June 16-19, 2025
Boston Convention Center
Boston, MA
BIO INTERNATIONAL CONVENTION
Conference information: BIO 2025
Past Events
2025
January 13-16, 2025
2024
December 4, 2024
November 6-10, 2024
May 31 – June 4, 2024
April 5 – 10, 2024
February 26 – 28, 2024
January 8 – 11, 2024
BIO CEO & INVESTOR CONFERENCE
JP MORGAN 2024 42ND ANNUAL HEALTHCARE CONFERENCE
2023
November 3 – 5, 2023
SOCIETY FOR IMMUNOTHERAPY OF CANCERS (SITC) ANNUAL MEETING